James Gruber
Director of Finance/CFO chez ETON PHARMACEUTICALS, INC.
Fortune : 13 496 $ au 31/03/2024
Profil
James R.
Gruber is currently the Chief Financial Officer, Secretary & Treasurer at Eton Pharmaceuticals, Inc. He previously worked as the Vice President & Controller at Horizon Therapeutics, Inc. Gruber received an undergraduate degree from Indiana University and an MBA from Kellogg School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 13/02/2024 | 3 599 ( 0,01% ) | 13 496 $ | 31/03/2024 |
Postes actifs de James Gruber
| Sociétés | Poste | Début |
|---|---|---|
| ETON PHARMACEUTICALS, INC. | Director of Finance/CFO | 11/04/2022 |
Anciens postes connus de James Gruber
| Sociétés | Poste | Fin |
|---|---|---|
Horizon Therapeutics, Inc.
 Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Comptroller/Controller/Auditor | - |
Formation de James Gruber
| Indiana University | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Health Technology |
| Eton Pharmaceuticals, Inc. |
